An Eli Lilly drug helped obese patients with Type 2 diabetes lose 15% of their body weight, or about 34 pounds, on average, in a late-stage clinical trial, the drugmaker says.
helped obese patients with Type 2 diabetes lose 15% of their body weight, or about 34 pounds, on average, in a late-stage clinical trial, the drugmaker said in a news release Thursday.— which is sold under the brand name Mounjaro for Type 2 diabetes — can be used as an effective weight loss aid.found that tirzepatide helped patients without Type 2 diabetes lose 22.5% of their body weight on average, or about 52 pounds. Patients in that trial had obesity or were overweight.
The participants in the trial received a weekly injection of tirzepatide or a placebo for 72 weeks. Two doses of tirzepatide were studied: a 10-milligram dose and a 15 mg dose. Thursday’s results were announced in a news release and haven’t been made available for peer review yet., said Dr. Susan Spratt, an endocrinologist and senior medical director for the Population Health Management Office at Duke Health in North Carolina.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly stock up premarket as company’s Q1 revenue beats and it raises guidanceEli Lilly & Co. shares rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance....
Read more »
Popular diabetes drug Mounjaro could be FDA-approved for weight loss this year, company saysA popular drug currently approved to treat Type 2 diabetes could soon also be approved for weight loss.
Read more »
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO saysBiogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.
Read more »
Eli Lilly’s tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in late-stage trialEli Lilly & Co. said Thursday its tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in a late-stage...
Read more »
Rep. Eli Crane rips federal agency over tribal mine delaysRep. Eli Crane wrote to Interior Secretary Deb Haaland to encourage the feds to cut red tape holding up the tribe's mines.
Read more »